Back to top
more

Sutro Biopharma (STRO)

(Delayed Data from NSDQ)

$0.81 USD

0.81
233,544

0.00 (0.58%)

Updated Aug 1, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?

by Zacks Equity Research

Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?

by Zacks Equity Research

Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?

by Zacks Equity Research

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

RGC Resources (RGCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength?

by Zacks Equity Research

Mobileye (MBLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 0% and 345.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -24.41% and 83.48%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -3.49% and 34.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of 20.47% and 7.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -58.33% and 98.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 20.27% and 53.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

by Zacks Equity Research

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 22.37% and 2.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

XOMA Royalty (XOMA) delivered earnings and revenue surprises of -7.69% and 32.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Repare Therapeutics (RPTX) delivered earnings and revenue surprises of 3.53% and 73.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -0.96% and 7.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 37.84% and 1.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Sutro Biopharma (STRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.